



PHARMA'S AGE OF UNCERTAINTY

WORLD PREVIEW 2023 TO 2028

TODAY'S PRESENTERS

World preview 2022 to 2023



PAUL VERDIN

VP, Head of Consulting
& Analytics, Evaluate



MELANIE SENIOR

Author, World
Preview 2023



DANIEL CHANCELLOR

Thought Leadership and
Consulting Director, Evaluate



AGENDA

Our annual World Preview report draws on data from Evaluate Pharma and Evaluate Omnium and considers the current state of the market as well as providing our latest forecast data out to 2028.

- The 5 forces of uncertainty
- The outlook to 2028
- Discussion: the big issues ahead



THE CURRENT ENVIRONMENT

Despite all this, the market has a CAGR of +5.9% from 2023-2028



REGULATORY UNCERTAINTY

The FDA is a source of uncertainty for drug developers and questions are being asked about the Accelerated Approvals pathway.



LEGISLATIVE UNCERTAINTY

The IRA is set to curb profits on high-spend drugs and limits price rises.



COMMERCIAL UNCERTAINTY

The patent cliff is upon us and there are questions about who'll pay for future blockbusters.



DEALMAKING UNCERTAINTY

The IRA is impacting deal making and the FTC is expanding its reach (though has been pushed back for now).



R&D UNCERTAINTY

Understanding where to invest is more challenging than ever, with new modalities and the rise of RNA-based and gene-edited medicines.


THE OUTLOOK TO 2028



TOTAL WORLDWIDE PHARMACEUTICAL SALES

Market growth set to continue at +5.9% CAGR 2023-2028

Worldwide Total Prescription Drug Sales (2014-2028)




After reaching \$1tn during COVID, industry revenues will accelerate from 2023

Growth will be catalysed by several factors
Continued oncology growth


- Therapeutic advances in untreated rare diseases and SOC advances in common chronic diseases
- Novel modalities becoming mainstream therapeutics
- AI-ML enabling greater R&D efficiency and deeper product pipelines

Downward pressure from global efforts to control the cost of healthcare will impact revenue for a number of top-tier firms

WORLDWIDE SALES AT RISK FROM PATENT EXPIRATION (2014-2028)



TOP TEN COMPANIES IN 2028



CAGR	5.3%	4.5%	2.3%	2.9%	-6.9%	2.6%	4.7%	5.1%	12%	11.2%
Rank Change	+5	+3	-1	-1	-4	-2	+1	+1	+5	+3

TOP TEN PRODUCTS IN 2028

Top 10 Selling Products Worldwide in 2028




CAGR	9.8%	20.3%	22.2%	-	18.5%	9.5%	30.4%	6.7%	12.5%	10.8%
Rank Change	+3	+14	+22	+2928	+12	+4	+48	+1	+9	+9

WORLDWIDE PRESCRIPTION DRUG & OTC SALES

By therapy area in 2028

Chart 8: Top 10 Therapy Areas in 2028, Market Share & Sales Growth



THANK YOU

www.evaluate.com

EVALUATE HEADQUARTERS

Evaluate Ltd
3 More London, Riverside
London SE1 2RE
United Kingdom

T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

EVALUATE AMERICAS

EvaluatePharma USA Inc.
265 Franklin, Suite 1101
Boston MA 02109
USA

T +1 617 573 9450
F +1 617 573 9542

EVALUATE ASIA PACIFIC

Holland Hills Mori Tower 2F
5-11-2 Toranomom, Minato-ku
Tokyo 105-0001
Japan

T +81 (0) 70 4131 0112

Evaluate[↗]
a norstella company